Pfizer to Acquire Global Blood Therapeutics inc.

Pfizer and Global Blood Therapeutics inc. reached an agreement under which Pfizer will acquire GBT for the total enterprise value of 5.4 billion. Under the terms of the transaction, Pfizer will buy total outstanding shares at $68.5 per share in cash.

The acquisition will further enhance Pfizer’s rare hematology and sickle cell disease capabilities.